TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clinical accuracy of the antibody and antigen rapid tests based on Clinical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-test interpretation of result vs expert clinical image interpretation of result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of reportable EUHASS events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Were Symptom Free at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Glutamate to Creatine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of peripheral blood markers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 8-Week Disease Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in clinical attachment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in periodontal probing pocket
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in body fatness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in total energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Insulin-Independent Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of patients with complete cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of venous thromboembolism (VTE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Surgical successful rate without leakage of cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Mean of Total Score of Asthma Control Questionnaire (ACQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HOMA (Homeostasis Model Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IL-6 (Interleukin 6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Oncological safety
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Patients Achieving ≥ 75% Decrease in PSSI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for Quinine Sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Quinine Sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Quinine Sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence and severity of differentiation syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: urinary biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Flow Mediated Vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitroglycerin Induced Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin Blood Flow Before and After Iontophoresis With Acetylcholine and Sodium Nitroprusside
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: preadipocyte proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FDI Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Plasma Concentration (Cmax) of Colchicine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Hb concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Effects on growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effects on the adrenal cortical function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Effects on development of infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in CompACT score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in CompACT short form score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in DASS-21 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Controlling of hyperphosphatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of the common carotid artery blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Romberg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sharpened Romberg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: One-leg stance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Timed up and go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mini-Balance Evaluation Systems Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Montreal Cognitive Assessment Chinese version
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Stent graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Image Diagnostic Quality for Phase 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image Diagnostic Quality for Phase 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced an Adverse Event in Phase 1
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experienced an Adverse Event in Phase 2
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Histologic Progression Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Radiologic Progression Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Trail Making Test Part A (TMT-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: DAMPs levels in systemic circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of sustained clinical VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects Who Experienced Sustained Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on the Advocacy Behavior Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Proportion of subjects in clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cured (Reduction in dimension greater than 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days between therapeutic initiation and childbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: SF-12 Physical Component Summary (PCS) at week 26
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global pain VAS score at week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in horizontal width from post-extraction site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who received Human Serum Albumin (HSA) containing drug
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who received HSA-free drug
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who received epoetin alfa intravenously
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of Life/Well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Achievement of Insulin Independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Youth's psychological capacity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Youth's physical capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Youth's social factors
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Height of augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in trait mindfulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensitivity of in-clinic dermatologist diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of in-clinic dermatologist diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen (PSA) objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference of land-marking method
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete cure of the target great toenail
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: tumor recurrent status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: absence of atrial fibrillation at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Swallowing act
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in skeletal muscle mitochondrial number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants treated according to protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Positive Anti-etanercept Binding Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: success rate of tracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient prognosis
Endpoint domain: Mortality/survival
Primary endpoint: physical and psychological stress of medical staff
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Terminal Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy Procedure-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Injection Procedure-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: AMDC Product-related Events
Endpoint domain: Adverse events/effects
Primary endpoint: Confirmed Tumor Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: motion in the STT joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in inflammation (CRP, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 3 year survival rate
Endpoint domain: Mortality/survival
Primary endpoint: PAI-1 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oxygen saturation variation during DISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: heart rate variation during DISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic and diastolic blood pressure variation during DISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: adverse events during DISE
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial function as flow mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic effects accompanying steroid administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Events related to nervous system, musculoskeletal system and circulatory systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hamstrings flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular Disease (CVD) Risk Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of FURESTEM-RA Inj. treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Procedural Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose Area Product of Radiation Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of residual valvular or paravalvular regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Radiation Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoroscopy Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean area under the curve (AUC) of plasma concentration vs. time of total 6-prenylnaringenin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve (AUC) of plasma concentration vs. time of total 8-prenylnaringenin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum plasma concentration (Cmax) of total 6-prenylnaringenin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum plasma concentration (Cmax) of total 8-prenylnaringenin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in time to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls Efficacy Scale-International (FES-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Area Under the Curve (AUC) of Breath CH4 Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Dental Caries Increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Successfully Transitioned Off Buprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal features measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of Liver Function Test (LFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV 6 Serum Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV 11 Serum Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV 16 Serum Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HPV 18 Serum Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in morning total testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Function disability of the shoulder
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Event reporting rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Type 1 Diabetes Mellitus
Endpoint domain: Mortality/survival
Primary endpoint: Completion of sleep hygiene log
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Completion of morning sleep log
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Completion of Leeds Sleep Evaluation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Dose changes of Tyvaso
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Veliparib
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose Limiting Toxicity
Primary endpoint: Local toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic photosensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as Determined by Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Low Back Pain Rating Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Back Pain Rating Oswestry Low Back Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life Rating Short Form 12-item (SF-12) Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physiologic functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Antioxidant Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Oxidant Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Resolution of Anterior Chamber Cells and Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Grade 0 (no) Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of plasma lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: calcification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitral Regurgitation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gingival crevicular fluid protein content change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Accuracy on the EF Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in Response Times (RTs) on the EF Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: International Index of Erectile Function (IIEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile Dysfunction (EPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine IL-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NT-ProBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apixaban area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apixaban maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaper dermatitis severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Seroprevalence of antibodies to AAV vectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of Seroconversion of antibodies to AAV vectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of PDR and/or DME
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Change in Visual Acuity From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Prevalence of traumatic oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of adverse drug reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Molecular Complete Remission (MCR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Alive at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients Who Experienced Relapse by 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Breast Tissue Volume/Appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of A/H5N1 influenza virus vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of organ preservative strategies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Radiation induced skin reaction
Endpoint domain: Adverse events/effects